Humana (NYSE:HUM) Given New $602.00 Price Target at Wells Fargo & Company

Humana (NYSE:HUM) had its price objective boosted by Wells Fargo & Company from $502.00 to $602.00 in a research note issued to investors on Thursday, Benzinga reports. The brokerage presently has an “overweight” rating on the insurance provider’s stock. Wells Fargo & Company‘s price target indicates a potential upside of 34.88% from the stock’s current price.

Several other research firms have also commented on HUM. Lake Street Capital assumed coverage on Humana in a research report on Thursday, July 30th. They set a “buy” rating on the stock. Zacks Research raised shares of Humana from a “hold” rating to a “strong-buy” rating in a research report on Tuesday. Morgan Stanley upgraded shares of Humana from an “underweight” rating to an “overweight” rating in a research note on Friday, October 9th. Mizuho boosted their target price on shares of Humana from $468.00 to $495.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 13th. Finally, JPMorgan Chase & Co. upped their target price on shares of Humana from $393.00 to $484.00 and gave the company a “neutral” rating in a research note on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $476.52.

Humana Trading Up 1.9%

NYSE:HUM opened at $446.33 on Thursday. The business’s 50-day moving average is $406.79 and its two-hundred day moving average is $314.80. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.65 and a quick ratio of 1.74. Humana has a 12 month low of $163.11 and a 12 month high of $456.50. The firm has a market capitalization of $53.60 billion, a PE ratio of 43.42, a price-to-earnings-growth ratio of 2.30 and a beta of 0.65.

Humana (NYSE:HUM) last issued its earnings results on Friday, November 6th. The insurance provider reported ($0.70) earnings per share for the quarter, topping the consensus estimate of ($1.00) by $0.30. Humana had a return on equity of 8.50% and a net margin of 0.81%. The company had revenue of $41.16 billion during the quarter, compared to the consensus estimate of $40.87 billion. During the same quarter in the prior year, the business earned $3.24 earnings per share. The company’s revenue was up 26.1% compared to the same quarter last year. Humana has set its FY 2026 guidance at 9.500- EPS. Research analysts predict that Humana will post 9.56 earnings per share for the current fiscal year.

Institutional Trading of Humana

A number of hedge funds have recently made changes to their positions in HUM. Rothschild Investment LLC grew its holdings in Humana by 9.4% during the 3rd quarter. Rothschild Investment LLC now owns 279 shares of the insurance provider’s stock worth $106,000 after acquiring an additional 24 shares in the last quarter. Pinnacle Wealth Planning Services Inc. raised its stake in shares of Humana by 21.8% in the 3rd quarter. Pinnacle Wealth Planning Services Inc. now owns 151 shares of the insurance provider’s stock valued at $58,000 after purchasing an additional 27 shares in the last quarter. Wilkerson Advisory Group LLC raised its stake in shares of Humana by 24.6% in the 2nd quarter. Wilkerson Advisory Group LLC now owns 167 shares of the insurance provider’s stock valued at $66,000 after purchasing an additional 33 shares in the last quarter. Moors & Cabot Inc. lifted its position in shares of Humana by 4.3% during the third quarter. Moors & Cabot Inc. now owns 804 shares of the insurance provider’s stock worth $307,000 after purchasing an additional 33 shares during the last quarter. Finally, Cidel Asset Management Inc. lifted its position in shares of Humana by 1.1% during the second quarter. Cidel Asset Management Inc. now owns 3,883 shares of the insurance provider’s stock worth $1,542,000 after purchasing an additional 41 shares during the last quarter. Institutional investors and hedge funds own 92.38% of the company’s stock.

Humana News Summary

Investors following HUM have been watching these news items:

• Positive Sentiment: JPMorgan raised its price target to $484 from $393 while maintaining a Neutral rating, and a separate report said the bank sees Humana’s shares as positioned to rise. The higher target adds to favorable post-earnings analyst attention. JPMorgan view on Humana shares
• Positive Sentiment: Humana’s new oncology-care model with Evolent and American Oncology Network aims to streamline cancer treatment by reducing prior-authorization hurdles. The initiative may support its broader value-based-care strategy, though its financial impact is not yet clear. Oncology model analysis
• Negative Sentiment: TD Cowen raised its target to $430 from $370 but kept a Hold rating; that target is below the $446.33 reference price, offering a more cautious counterpoint to recent bullish calls. Analyst and company updates

About Humana

Humana Inc. is a U.S. health and wellness company that provides health insurance and healthcare services. Its insurance offerings include Medicare Advantage, Medicare Supplement and prescription drug plans, as well as Medicaid and employer-sponsored plans. The company also provides care through CenterWell, its healthcare services brand, which includes primary care, home health and pharmacy services. Its insurance and care offerings are available in markets across the United States, with availability varying by product and location.